X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MCO-010 (sonpiretigene isteparvovec) is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette. It is being evaluated for the treatment of retinitis pigmentosa.
Lead Product(s): Sonpiretigene Isteparvovec
Therapeutic Area: Genetic Disease Product Name: MCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
MCO-010 (sonpiretigene isteparvovec) is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP).
Lead Product(s): Sonpiretigene Isteparvovec
Therapeutic Area: Genetic Disease Product Name: MCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Through this partnership, Nanoscope will have access to established manufacturing platforms and multiple Charles River CDMO centers of excellence. The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin gene expression cassette.
Lead Product(s): vMCO-010
Therapeutic Area: Genetic Disease Product Name: vMCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Charles River Laboratories, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 18, 2022
Details:
This multicenter, randomized, double-masked, sham-controlled, dose-ranging study will evaluate 2 dose levels of vMCO-010 in up to 18 subjects with retinitis pigmentosa (9 per dose).
Lead Product(s): vMCO-010
Therapeutic Area: Genetic Disease Product Name: vMCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Nanoscope’s MCO-020 gene therapy program is based on targeted laser-delivery of optogenes to areas of geographic atrophy in advanced AMD patients, and currently undergoing IND-enabling studies.
Lead Product(s): MCO-020
Therapeutic Area: Ophthalmology Product Name: MCO-020
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010).
Lead Product(s): vMCO-010
Therapeutic Area: Genetic Disease Product Name: vMCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
This multicenter, randomized, double-masked, sham-controlled, dose-ranging study will evaluate 2 dose levels of vMCO-010 in up to 18 subjects with retinitis pigmentosa (9 per dose). Nine subjects will receive sham injection.
Lead Product(s): vMCO-010
Therapeutic Area: Genetic Disease Product Name: vMCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2022
Details:
vMCO-010, an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration, demonstrated a favorable safety profile and several patients experienced restoration of vision in Phase 1/2a open-label trial.
Lead Product(s): MCO-010
Therapeutic Area: Genetic Disease Product Name: vMCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Nanoscope Therapeutics lead product MCO-010, is in a Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial in the U.S. for treatment of retinitis pigmentosa.
Lead Product(s): MCO-010
Therapeutic Area: Ophthalmology Product Name: MCO-010
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Nanoscope’s lead MCO gene therapy, MCO-010, is in a late-stage Phase 2b trial for retinitis pigmentosa (RP) in the US. MCO-010 has orphan drug designations for RP and Stargardt disease from the US Food and Drug Administration.
Lead Product(s): MCO-010
Therapeutic Area: Ophthalmology Product Name: MCO-010
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding September 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
